IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.209
NA - Nord America 4.333
AS - Asia 4.169
SA - Sud America 738
AF - Africa 52
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.518
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.250
RU - Federazione Russa 2.243
SG - Singapore 1.603
IE - Irlanda 1.246
CN - Cina 869
HK - Hong Kong 757
IT - Italia 742
BR - Brasile 622
DE - Germania 440
GB - Regno Unito 407
UA - Ucraina 356
KR - Corea 294
FR - Francia 265
VN - Vietnam 202
FI - Finlandia 140
IN - India 124
SE - Svezia 113
GR - Grecia 105
TR - Turchia 97
JP - Giappone 77
CA - Canada 50
AR - Argentina 45
AT - Austria 35
PK - Pakistan 34
BD - Bangladesh 25
EC - Ecuador 22
NL - Olanda 22
BE - Belgio 21
ID - Indonesia 21
MX - Messico 20
CZ - Repubblica Ceca 16
ZA - Sudafrica 15
IQ - Iraq 13
PL - Polonia 13
ES - Italia 12
MA - Marocco 11
PY - Paraguay 9
VE - Venezuela 9
AU - Australia 8
BO - Bolivia 8
PE - Perù 8
CL - Cile 7
IR - Iran 7
KE - Kenya 7
NZ - Nuova Zelanda 7
CH - Svizzera 6
AZ - Azerbaigian 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
HU - Ungheria 4
LT - Lituania 4
TN - Tunisia 4
UZ - Uzbekistan 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
MK - Macedonia 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
BY - Bielorussia 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
NP - Nepal 2
RS - Serbia 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
BG - Bulgaria 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TL - Timor Orientale 1
Totale 15.518
Salva come PNG Salva come JPEG
Città #
Dublin 1.233
Hong Kong 754
Moscow 752
Santa Clara 674
Singapore 640
Chandler 607
Jacksonville 581
Seoul 271
Princeton 170
Beijing 147
Bremen 145
Roxbury 142
New York 140
Medford 131
Hefei 128
Dallas 123
Naples 114
Ann Arbor 106
Ashburn 106
Munich 105
The Dalles 84
Wilmington 78
Bengaluru 77
Caserta 76
Ho Chi Minh City 67
São Paulo 65
Los Angeles 55
Boardman 54
Cambridge 45
Des Moines 42
San Mateo 41
Nanjing 38
Woodbridge 36
Hanoi 34
Napoli 32
Turku 32
Nuremberg 25
Elora 22
Falkenstein 22
Brussels 21
Tianjin 21
Dong Ket 20
Norwalk 20
Vienna 20
Brasília 19
Helsinki 17
Houston 17
Mountain View 17
Rio de Janeiro 17
Shanghai 17
Milan 15
Tokyo 15
Belo Horizonte 13
Brno 13
Brooklyn 13
Guangzhou 13
Nanchang 13
Columbus 12
Curitiba 12
Aversa 11
Istanbul 11
Düsseldorf 10
Jakarta 10
Lappeenranta 10
Quito 10
Redwood City 10
Rome 10
San Francisco 10
Auburn Hills 9
Changsha 9
Jinan 9
Warsaw 9
Amsterdam 8
Bahawalpur 8
Council Bluffs 8
Ercolano 8
Frankfurt am Main 8
Guarulhos 8
London 8
Rawalpindi 8
Zhengzhou 8
Cava Dei Tirreni 7
Groningen 7
Haiphong 7
Hangzhou 7
Hải Dương 7
Ninh Bình 7
Ottawa 7
Pozzuoli 7
Toronto 7
Venice 7
Da Nang 6
Dhaka 6
Florence 6
Goiânia 6
Guayaquil 6
Johannesburg 6
Manchester 6
Mauá 6
Nairobi 6
Totale 8.643
Salva come PNG Salva come JPEG
Nome #
ONCOLOGIA MEDICA 171
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 168
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 148
Beyond N staging in colorectal cancer: Current approaches and future perspectives 145
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 145
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 136
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 130
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 129
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 126
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 125
AXL is an oncotarget in human colorectal cancer 125
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 118
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 116
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 116
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 114
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 112
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 111
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 111
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 110
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 110
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 110
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 109
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 108
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 107
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 106
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 106
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 106
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 102
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 100
TRASTUZUMAB RESISTANCE IN BREAST CANCER 100
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 100
Farmacogenomica e cancro colorettale 99
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 98
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 96
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 96
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 96
The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria 95
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 95
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 95
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 95
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 94
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 93
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 93
Chemoradiotherapy as adjuvant treatment of gastric cancer 93
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 93
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 92
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 92
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 92
Targeting EGFR in Pancreatic Cancer Treatment. 92
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 92
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 92
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 90
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 90
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 90
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 90
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 90
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 88
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 88
Light alcohol drinking and the risk of cancer development: a controversial relationship 88
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 88
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 87
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 87
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 86
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 86
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 86
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 85
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)] 85
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 85
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 84
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 83
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 83
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 82
Metformin in lung cancer: rationale for a combination therapy 82
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 82
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. 82
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 82
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 82
Preoperative chemo-radiotherapy for carcinoma of the esophagus 81
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 81
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 81
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 81
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 80
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 80
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 79
The new European gold standard treatment for rectum cancer 79
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 79
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 79
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 79
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 79
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 78
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 78
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 78
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 78
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 78
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 78
It is finally time for adjuvant therapy in melanoma 78
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 77
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 77
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 77
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer 76
Totale 9.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.088
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021557 0 0 0 0 0 12 129 95 34 116 120 51
2021/20221.151 54 17 23 23 340 20 42 35 54 99 106 338
2022/20232.473 251 50 34 212 291 208 7 151 1.149 17 57 46
2023/2024992 93 37 38 51 335 140 19 24 11 14 74 156
2024/20253.318 56 105 54 107 471 432 339 320 471 448 268 247
2025/20265.277 559 606 669 682 1.097 1.664 0 0 0 0 0 0
Totale 16.001